A Novel Orally Administered Antimalarial

VTIP 20-048: “Discovery of an Orally-Active Tetracyclic Antimalarial”

THE CHALLENGE
While current malarial drugs are able to protect against some strains, new malarial drugs are urgently needed to combat drug resistant malaria infection.

Also current malarial drugs cannot be administered orally, which reduces the potential for safe drug delivery.

OUR SOLUTION
Paul Carlier and team have created a structurally novel compound that inhibits the growth of malaria parasite in red blood cells. It is non-toxic to human cells suggesting parasite targeting mechanism of the compound. It can even be orally administered without any gastro-intestinal distress.

It shows an efficacy similar to that of chloroquine with added efficacy against drug resistant strains, thus a superior drug.